Skip to main content
Guidance

Hib/MenC: patient group direction (PGD) template

PGD template to support the national Haemophilus influenzae type b and meningococcal C conjugate vaccination programme.

Updates to this page

From:
UK Health Security Agency
Published:
4 February 2016
Last updated:
3 June 2025
Show all updates

  1. Added version 6 - see page 3 for change history.

  2. Added 'Notice of extension of the validity of Hib/MenC PGD'.

  3. Added version 5.

  4. Added V04.00: routine review.

  5. Updated template to align with new guidance for the public health management of Meningococcal disease in the UK.

  6. Updated to reflect removal of monovalent MenC from routine programme.

  7. First published.

This publication was withdrawn on

This PGD was withdrawn on the 30 April 2026 due to the cessation of routine Hib/MenC vaccination. Further information is available in the Childhood schedule changes 2025 and 2026: information for healthcare practitioners guide.

Applies to England

Documents

[Withdrawn] Hib/MenC: patient group direction (PGD) template

Ref: UKHSA gateway number GOV-18478

MS Word Document, 158 KB

This file may not be suitable for users of assistive technology.

Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of Haemophilus influenzae type b (Hib) and meningococcal C conjugate vaccine to individuals born on or before 30 June 2024 from their first birthday to under 10 years of age in accordance with the national immunisation programme; and to individuals of any age for the prevention of secondary cases of meningococcal group C (MenC) disease in accordance with the Guidance for the public health management of meningococcal disease in the UK.

Hib/MenC PGD version 6.0 is valid from 1 July 2025 to 30 April 2026, when it is anticipated all centrally held stocks of Menitorix®will expire. Once locally held stocks are depleted and Menitorix® is no longer available from ImmForm, the authorising manager (as per section 7 of the PGD) should retire this PGD.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Sign up for emails or print this page

Related content